Direct lending underwriting model: Xponential's 83% addbacks

A direct lender underwrites Xponential Fitness's first lien term loan in Compound from its credit agreement, 8-Ks, 10-Ks and 10-Qs: historicals with every addback, a lender case that haircuts the recurring ones, management and downside cases, covenant headroom by quarter through the step-downs, and the all-in yield off the SOFR forward curve beside two BDCs' marks.

Compound Research · Updated Nov 19, 2026 · 15 min read

Short answer

A direct lending underwriting model sizes a senior loan against the lender's own view of EBITDA: addbacks haircut, cases stressed, covenants tested and the loan priced. In Compound's model of Xponential Fitness's $525 million first lien term loan, addbacks are 83% of Adjusted EBITDA, and the lender-case haircuts take leverage from 5.9x to 7.9x.

Try it now
On this page (10)
  1. 1. Choosing the borrower: Xponential Fitness and its HPS term loan
  2. 2. Reported EBITDA to Adjusted EBITDA: addbacks of 82.6%
  3. 3. The lender case haircuts: costs that keep coming back
  4. 4. Three cases over five years
  5. 5. Covenant headroom by quarter and the March 2028 step-down
  6. 6. Coverage, free cash flow and liquidity
  7. 7. Pricing: all-in yield to take-out and maturity, and the BDC marks
  8. 8. What the public filings cannot tell you
  9. 9. Our view
  10. 10. FAQ

Compound’s direct lending underwriting model of Xponential Fitness starts from a gap: reported EBITDA of $15.6 million for the twelve months to September 30, 2026 against management’s Adjusted EBITDA of $89.5 million. Addbacks are 82.6% of the adjusted figure. After the lender case’s haircuts, chiefly half credit for litigation costs that recur every year and a quarter of the restructuring charges, lender EBITDA is $67.3 million, and the $531.1 million of debt is 7.9x that figure against 5.9x on management’s.

Carried forward, all three cases test above the 5.00x leverage covenant when it steps down on March 31, 2028: the management case at 5.06x, the lender case at 6.10x, and the downside case, sized to the company’s FY2020, breaches in June 2027. The lender case runs out of liquidity in the third quarter of 2028. These are the model’s results under its haircuts and its projections, and the years after 2026 are Compound’s own assumptions, because the company gives no multi-year guidance. They are not a forecast of a default and not a view on the company, its lenders or its securities. One more caveat sits at the start: the request asked for a sponsor-backed borrower, and Xponential is not sponsor-controlled. Compound said so and used it as a stand-in.

You are underwriting a senior secured loan to a middle-market company. You need the terms from the documents, an EBITDA you would lend against, cases that show where the covenant and the cash run out, and a yield that reflects the OID. We asked Compound to build that model on a real borrower from public filings. It ran on November 19, 2026 and returned one Excel workbook of eight sheets and a short written answer.

What the workbook shows:

  • The borrower and the loan. A $525 million first lien term loan and a $25 million revolver closed on December 8, 2025, with HPS Investment Partners as agent, priced at SOFR + 6.75% with a 1.00% floor and 3.4% OID. The only financial covenant is maximum total net leverage.
  • The addbacks. $73.9 million of addbacks on $15.6 million of reported EBITDA in the last twelve months, led by $27.1 million of litigation and a $27.3 million loss on debt extinguishment.
  • The lender view. Fifteen addbacks, each with a credit percentage and a reason. The haircuts take $22.2 million, 24.8%, off management’s figure and add 1.96 turns of leverage.
  • Three cases to the December 2030 maturity. Management from guidance, lender with lower growth and margins, and a downside that repeats FY2020.
  • Covenant headroom by quarter. 18.7% at September 30, 2026, then negative in every case at the March 2028 step-down.
  • The pricing. An all-in yield of 13.28% to a three-year take-out and 12.84% to maturity, beside the cost and fair value at which two BDCs carry the loan.

The loan terms come from the 8-K of December 8, 2025 and the credit agreement filed as its Exhibit 10.1, the historicals and guidance from Xponential’s 10-Ks, 10-Qs and earnings releases, and the BDC holdings from the September 30, 2026 schedules of investments of Fortress Private Lending Fund and HPS Corporate Capital Solutions Fund, all on SEC EDGAR. Settlement payments and cost review commentary come from the Q3 2026 earnings call, and floating-rate interest from the SOFR forward curve of November 19, 2026. Every other input is marked as an analyst assumption with a reason.

Prompt to try

“I am underwriting a senior secured loan to a sponsor-backed company and want a direct lending underwriting model built on a real borrower. From SEC EDGAR, pick one U.S. public company with under $250 million of EBITDA that in the last 24 months disclosed a senior secured term loan or unitranche from a private credit lender (a BDC or direct lending fund), with the credit agreement filed as an exhibit. Take the pricing, amortization, maturity, fees and financial covenant levels from the credit agreement or the 8-K. Build historicals for the last three fiscal years and the latest twelve months from the 10-K and 10-Q, showing reported EBITDA, each addback management takes, and Adjusted EBITDA. Build three cases over five years: a management case from company guidance or the latest earnings call; a lender case that haircuts the addbacks I would not give full credit for and lowers growth and margins, with a note on each haircut; and a downside case sized to a recession like the company's own worst year. For each case show total and senior net leverage, interest coverage, fixed charge coverage, free cash flow after debt service, liquidity from cash plus undrawn revolver, and headroom to each financial covenant by quarter for the first two years. Price the loan off the SOFR forward curve plus the contractual spread and floor, with the OID and fees, and show the all-in yield to a three-year take-out and to maturity. If a public BDC lists this loan in its schedule of investments, show its cost, fair value and spread next to the model. Flag lender-case leverage above 6.0x, fixed charge coverage below 1.2x, covenant headroom below 20% in any quarter, and liquidity below six months of fixed charges in the downside case. Use the stored public data wherever it has the figure, and web search only for what it lacks. Put every input on an Assumptions sheet with one column that says where it came from: a cited source, or "analyst assumption" for a figure I would set myself, with the reason for the value you chose. Every output must be a live formula that traces back to the Assumptions sheet. Add a Sources sheet listing each data source, what it gave and its date. Deliver one Excel workbook and a short summary of the result, the flags, and what I would need from the sponsor and management to firm it up. Cite every sourced figure.”

Try this prompt free →

That is the request as we sent it, without its closing line, which asks that no name or email be put in the workbook.

Choosing the borrower: Xponential Fitness and its HPS term loan

Compound picked Xponential Fitness, a franchisor with $89.5 million of last-twelve-month Adjusted EBITDA, whose December 2025 refinancing is a private credit term loan with the credit agreement on file. It is not sponsor-controlled, and the answer says so: “Xponential is not sponsor-controlled, so it stands in for your borrower.”

XPOF_Direct_Lending_Underwriting_Model.xlsx
D10fx="Term SOFR + "&TEXT(Assumptions!D15,"0.00%")&" (grid down to "&TEXT(Assumptions!E35,"0.00%")&"), "&TEXT(Assumptions!D14,"0.00%")&" floor, OID "&TEXT(Assumptions!D16,"0.0%")&", issue price "&TEXT(Assumptions!D19,"0.0%")
BD
5FACILITY
6BorrowerXponential Fitness LLC (subsidiary of Xponential Fitness, Inc., NYSE: XPOF)
7Agent and lendersHPS Investment Partners LLC, as agent; private credit lender group
8Facilities$525M first lien term loan and $25M revolver
9Closing and maturityDec 8, 2025 to Dec 8, 2030
10PricingTerm SOFR + 6.75% (grid down to 5.75%), 1.00% floor, OID 3.4%, issue price 96.4%
11Amortization1.0% a year in 2026, 3.0% in 2027, 5.0% from 2028; 50% ECF sweep
12Financial covenantMax Total Net Leverage 7.00x through 2026, 6.25x in 2027, 5.00x from Q1 2028
13Call protectionPremium of 3% / 2% / 1% in years 1-3
SummaryAssumptionsHistoricalsMgmt CaseLender CaseDownside CaseLoan PricingSources
The facility block from Compound's Summary tab, rows 5 to 13, unedited. Each line is a formula that assembles the terms from the Assumptions sheet.

The credit agreement sets more than the headline terms, and the Assumptions sheet carries each clause with its section. The margin steps down a grid on first lien net leverage, from 6.75% at 4.25x and above to 5.75% below 3.50x. The model holds 6.75% throughout because leverage stays above 4.25x in every case. The unused revolver fee is 0.50%. Unrestricted cash netted in the leverage test is capped at $50 million. The excess cash flow sweep is 50%, stepping to 25% at 3.5x first lien net leverage and to nothing at 3.0x, and the prepayment premium runs 3%, 2% and 1% over the first three years.

The OID comes from the Q3 2026 10-Q, which also gives net proceeds of $506.2 million. The gap between the two implies 0.19% of other upfront fees, so lenders funded at 96.41% of par. The revolver was first drawn for $10.0 million on April 7, 2026, and term loan principal was $521.1 million at September 30, 2026. Total debt of $531.1 million is the starting point for every ratio below. The credit agreement analysis page covers that clause-by-clause review.

Reported EBITDA to Adjusted EBITDA: addbacks of 82.6%

For the twelve months to September 30, 2026, $73.9 million of addbacks turn $15.6 million of reported EBITDA into $89.5 million of Adjusted EBITDA. In FY2024 the addbacks were larger than Adjusted EBITDA itself.

XPOF_Direct_Lending_Underwriting_Model.xlsx
G33fx=G13+G32
BDEFG
5Period12/31/202312/31/202412/31/20259/30/2026
7Revenue ($000)317,937320,346314,879271,907
9Net income (loss)(6,443)(98,696)(53,671)(46,355)
10(+) Interest expense, net37,12244,42645,97753,759
11(+) Income taxes (benefit)1,034(342)1,322453
12(+) Depreciation and amortization16,88317,71312,0277,765
13Reported EBITDA ($000)48,596(36,899)5,65515,622
17(+) Equity-based compensation17,99715,46512,90810,287
19(+) Acquisition and transaction expenses (income)(18,464)8,886(6,948)(5,057)
20(+) Litigation expenses6,83932,57530,09727,125
21(+) Financial transaction fees and related expenses9,0386204085,301
23(+) Impairment of goodwill and other noncurrent assets16,75062,55132,718307
24(+) Loss and expenses due to brand divestitures and wind down-1,8205,5706,773
30(+) Loss on debt extinguishment--27,32727,327
31(+) Restructuring and related charges15,70026,2873,9792,123
32Total management addbacks51,725153,116106,12373,909
33Adjusted EBITDA, management ($000)100,321116,217111,77889,531
36Addbacks as % of Adjusted EBITDA51.6%131.8%94.9%82.6%
SummaryAssumptionsHistoricalsMgmt CaseLender CaseDownside CaseLoan PricingSources
The bridge from net income to Adjusted EBITDA from Compound's Historicals tab, rows 5 to 36, without the growth row, the check rows, the margin row and seven smaller addbacks. US$ thousands. The last column is the twelve months to September 30, 2026.

The bridge ties to the company’s reported figures in every period. Two lines dominate the last twelve months. Litigation expenses are $27.1 million, and the loss on debt extinguishment from the December 2025 refinancing is $27.3 million. Equity-based compensation adds $10.3 million and brand divestitures and wind-down $6.8 million, while acquisition and transaction income takes $5.1 million out, because it is mostly fair-value income on contingent consideration.

Management addbacks as a share of Adjusted EBITDA

Total addbacks over management Adjusted EBITDA. LTM is the twelve months to September 30, 2026

FY202351.6%FY2024131.8%FY202594.9%LTM to 9/30/202682.5%

Compound's Historicals tab, row 36: Xponential Fitness earnings releases and Form 10-K and 10-Q filings, FY2023 as corrected.

The pattern matters more than any one year. Litigation is added back in every period: $6.8 million in FY2023, $32.6 million in FY2024 and $30.1 million in FY2025. Restructuring charges are added back every year too, at $15.7 million, $26.3 million and $4.0 million. FY2023 was restated, and the sheet notes that Adjusted EBITDA was cut from $105.3 million to $100.3 million. Revenue in the last twelve months is $271.9 million, 13.6% below FY2025, partly from divestitures. Free cash flow after interest over the same twelve months is negative $13.7 million, which the sheet ties to litigation settlement payments and the higher interest bill after the refinancing. For how a credit team rebuilds an addback schedule, see adjusted EBITDA.

The lender case haircuts: costs that keep coming back

Compound gives full credit to the non-cash addbacks and cuts the cash costs that recur: half credit for litigation, financial transaction fees, brand wind-down and transformation costs, a quarter for restructuring, and none for executive transitions or payroll taxes on equity awards. That takes $22.2 million off last-twelve-month Adjusted EBITDA.

XPOF_Direct_Lending_Underwriting_Model.xlsx
BES
160Management addbackLenderHaircut note (analyst assumption)
161Equity-based compensation100%Full credit: non-cash, permitted by the Credit Agreement definition; RSU tax payments sit in other cash items
162Employer payroll taxes on equity-based compensation0%No credit: cash payroll tax that recurs with every vesting
163Acquisition and transaction expenses (income)100%Full credit: mostly fair-value changes in contingent consideration, non-cash; it deducts gains as well as adding back losses
164Litigation expenses50%50% credit: legal costs appear in every period FY2023-9M 2026 ($6.8M, $32.6M, $30.1M, $5.4M), so half is treated as run-rate; settlement-driven spikes credited at half pending a matter-by-matter schedule
165Financial transaction fees and related expenses50%50% credit: strategic and financing transaction fees recurred in FY2023 and 2026; cash cost
166TRA remeasurement100%Full credit: non-cash remeasurement of the tax receivable agreement
167Impairment of goodwill and other noncurrent assets100%Full credit: non-cash
168Loss and expenses due to brand divestitures and wind down50%50% credit: losses of exited brands are removable, but wind-down costs have recurred 2024-2026
169Executive transition costs0%No credit: CEO, CFO and COO transitions in 2024-2026 make leadership turnover recurring
170Non-recurring rebranding expenses100%Full credit: single occurrence in FY2024
171Transformation initiative costs50%50% credit: consulting spend in FY2024-FY2025 and a new cost review in 2027
172Contract settlement costs100%Full credit: single settlement in FY2024
173Other income (royalties from divested brands)100%Full credit: removes royalty income from divested brands (a deduction)
174Loss on debt extinguishment100%Full credit: financing cost of the Dec 2025 refinancing, not operating
175Restructuring and related charges25%25% credit: restructuring charges recur every year FY2023-9M 2026
SummaryAssumptionsHistoricalsMgmt CaseLender CaseDownside CaseLoan PricingSources
The lender credit percentage and haircut note for each addback from Compound's Assumptions tab, Section F, rows 160 to 175, without the management and downside columns (100% and the lender figure) and the cash-item flag.

Each note gives the reason in a line. Litigation gets half credit because “legal costs appear in every period”, so half is treated as run-rate, and settlement spikes are “credited at half pending a matter-by-matter schedule”. Restructuring gets a quarter because the charges “recur every year FY2023-9M 2026”. Executive transitions get nothing because the CEO, CFO and COO transitions of 2024 to 2026 “make leadership turnover recurring”. The lender keeps full credit for equity-based compensation, impairment, the tax receivable agreement remeasurement and the loss on debt extinguishment, all non-cash or financing items.

From management Adjusted EBITDA to lender EBITDA, last twelve months

Twelve months to September 30, 2026. Each step is the part of an addback the lender case does not credit

Management Adjusted EBITDA$89.5MPayroll taxes on equity awards (0% credit)($0.1M)Litigation expenses (50% credit)($13.6M)Financial transaction fees (50% credit)($2.7M)Brand divestitures and wind-down (50% credit)($3.4M)Executive transition costs (0% credit)($0.9M)Restructuring charges (25% credit)($1.6M)Lender-adjusted EBITDA$67.3MAxis starts at $64.0M

Compound's Historicals tab, the management and lender addback blocks, LTM column. Each step is the management addback less the amount the lender credits (our arithmetic); the steps sum to the $22.2 million haircut on row 57.

Litigation is the haircut that decides the number: $13.6 million of the $22.2 million (our arithmetic). It is also the judgment a credit committee will argue about. The last-twelve-month figure includes a $21.8 million litigation addback in the fourth quarter of 2025, while the nine months of 2026 carry only $5.4 million.

XPOF_Direct_Lending_Underwriting_Model.xlsx
G42fx=G20*Assumptions!$E$164
BDEFG
54Total addbacks credited by lender31,340114,12484,36751,689
55Lender-adjusted EBITDA ($000)79,93677,22590,02267,311
56Lender-adjusted EBITDA margin25.1%24.1%28.6%24.8%
57Haircut to management Adjusted EBITDA(20,386)(38,992)(21,756)(22,220)
58Haircut as % of management Adjusted EBITDA(20.3%)(33.6%)(19.5%)(24.8%)
60Memo: total debt at Sep 30, 2026 (term loan + revolver)531,063
61Memo: total leverage on management Adjusted EBITDA (x)5.93x
62Memo: total leverage on lender-adjusted EBITDA (x)7.89x
63Memo: leverage added by the haircuts (turns)1.96x
SummaryAssumptionsHistoricalsMgmt CaseLender CaseDownside CaseLoan PricingSources
The lender view's totals and the leverage memo at the foot of Compound's Historicals lender block, without a blank row. US$ thousands. Columns are FY2023, FY2024, FY2025 and the twelve months to September 30, 2026.

The haircut was 20.3%, 33.6% and 19.5% of Adjusted EBITDA in FY2023 to FY2025, so 24.8% today is no outlier. On the $531.1 million of debt at September 30, 2026, leverage is 5.93x management EBITDA and 7.89x lender EBITDA, 1.96 turns apart.

The haircuts feed the lender’s own statistics: total and senior leverage, interest coverage and fixed charge coverage. They do not feed the covenant test. Compound takes the company’s Adjusted EBITDA as covenant EBITDA, an assumption the answer names first among those “that change the answer”. The credit agreement permits these addbacks and run-rate items up to 25% of Consolidated EBITDA, so the covenant figure the borrower reports could be higher than the model’s.

Three cases over five years

The management case starts from the 2026 guidance midpoint of $92.5 million of Adjusted EBITDA, the lender case from the low end of $91.0 million with revenue down 3% in 2027, and the downside repeats FY2020 in 2027: revenue down 17.5% and Adjusted EBITDA down 40.5%.

The guidance was cut during the year, from $100 million to $110 million in February 2026 to $91 million to $94 million on November 5, 2026, with North America same store sales down 7.5% in the third quarter. The drivers after 2026 are Compound’s assumptions, each with a reason on the Assumptions sheet.

Driver (Assumptions, Section E)ManagementLenderDownside
FY2026E revenue$255.0 million, guidance midpoint$250.0 million, guidance low end$250.0 million
FY2026E Adjusted EBITDA$92.5 million$91.0 million$91.0 million
Revenue growth, FY2027E to FY2030E2%, 4%, 5%, 5%-3%, 0%, 2%, 2%-17.45%, 8%, 3%, 2%
Adjusted EBITDA margin, FY2027E to FY2030E36.5% rising to 38%35% then 34.5%26.25% rising to 33%
Addback creditFullHaircut as aboveHaircut as above

The downside is the request’s recession, sized to the company’s own worst year. FY2020, the year of studio closures, took revenue from $129.1 million to $106.6 million and Adjusted EBITDA from $16.5 million to $9.8 million, and the model applies both changes to FY2027.

XPOF_Direct_Lending_Underwriting_Model.xlsx
D39fx=IFERROR(INDEX('Mgmt Case'!$H$5:$AA$5,MATCH("Breach",'Mgmt Case'!$H$102:$AA$102,0)),"None")
BDEF
30MetricManagementLenderDownside
31FY2027E revenue ($000)260,100242,500206,366
32FY2027E Adjusted EBITDA, company definition ($000)94,93784,87554,172
33FY2027E credited EBITDA, case basis ($000)94,93776,85045,397
34Peak total leverage, credited EBITDA, Q4 2026-Q3 2028 (x)5.67x6.88x11.65x
35Peak senior secured net leverage, Q4 2026-Q3 2028 (x)5.51x6.71x12.11x
36Minimum interest coverage, Q4 2026-Q3 2028 (x)1.60x1.26x0.74x
37Minimum fixed charge coverage, Q4 2026-Q3 2028 (x)1.14x0.87x0.55x
38Minimum covenant headroom, Q4 2026-Q3 2028(1.2%)(22.4%)(82.2%)
39First covenant breach (quarter end)3/31/20283/31/20286/30/2027
40Cumulative FCF after debt service, FY2027E-FY2030E ($000)40,381(80,096)(150,315)
41Minimum liquidity, Q4 2026-Q3 2028 ($000)35,492(6,129)(53,128)
42Minimum liquidity in months of fixed charges, Q4 2026-Q3 20285.3(0.9)(7.6)
43Peak revolver drawn, Q4 2026-Q4 2030 ($000)4,50825,00025,000
44Lowest unrestricted cash, Q4 2026-Q4 2030 ($000; negative = funding gap)15,000(46,577)(116,643)
45Total leverage, credited EBITDA, FY2030E (x)3.74x5.51x6.26x
46Term loan outstanding at Dec 2030 maturity ($000)423,872425,250425,250
SummaryAssumptionsHistoricalsMgmt CaseLender CaseDownside CaseLoan PricingSources
The case results block of Compound's Summary tab, unedited. US$ thousands. Peaks and minimums cover the first two projection years, Q4 2026 to Q3 2028; credited EBITDA is after the case's haircuts.

In FY2027 the lender case’s credited EBITDA of $76.9 million is $18.1 million below management’s $94.9 million. Lower growth and margin account for $10.1 million of that and the haircuts for $8.0 million (our arithmetic). The haircuts shrink over time, from $12.9 million in FY2026 to $5.4 million a year from FY2028, because the lender case projects litigation at a $4.0 million to $5.0 million run-rate rather than at the settlement-year levels.

In every case about $424 million of the term loan is still outstanding at the December 2030 maturity: $423.9 million in the management case, where a small excess cash flow sweep is paid in 2030, and $425.3 million in the other two.

Covenant headroom by quarter and the March 2028 step-down

At September 30, 2026, covenant net leverage is 5.69x against 7.00x, 18.7% headroom. The covenant steps to 6.25x in March 2027 and to 5.00x in March 2028, and at that second step the management case tests at 5.06x and the lender case at 6.10x. The downside breaches at 6.99x in June 2027.

Total net leverage, covenant basis, against the covenant

Quarter ends, December 2026 to September 2028. Net debt over LTM company Adjusted EBITDA, cash netted up to $50 million

4.0x5.0x6.0x7.0x8.0x9.0x10.0xMar 2027Dec 2027Sep 2028Covenant maximumManagementLenderDownside

Compound's Summary tab, covenant headroom block, from the quarterly Mgmt Case, Lender Case and Downside Case tabs. Covenant levels from Section 7.12 of the credit agreement.

XPOF_Direct_Lending_Underwriting_Model.xlsx
I52fx='Mgmt Case'!P101
BDEFGHIJK
49Quarter end12/31/20263/31/20276/30/20279/30/202712/31/20273/31/20286/30/20289/30/2028
50Maximum Total Net Leverage (x)7.00x6.25x6.25x6.25x6.25x5.00x5.00x5.00x
51Management: total net leverage, covenant basis (x)5.51x5.27x5.13x5.12x5.20x5.06x4.92x4.79x
52Management: headroom (EBITDA cushion)21.4%15.7%17.9%18.0%16.9%(1.2%)1.6%4.3%
53Management: fixed charge coverage (x)1.43x1.40x1.35x1.27x1.20x1.17x1.15x1.14x
54Management: liquidity ($000)35,49235,85635,87635,72135,64435,68635,95736,345
55Lender: total net leverage, covenant basis (x)5.62x5.57x5.63x5.84x6.08x6.10x6.12x6.07x
56Lender: headroom (EBITDA cushion)19.7%10.8%9.9%6.5%2.8%(22.0%)(22.4%)(21.3%)
57Lender: fixed charge coverage (x)1.20x1.17x1.12x1.03x0.95x0.92x0.89x0.87x
58Lender: liquidity ($000)33,51928,99623,96618,60413,1816,549156(6,129)
59Downside: total net leverage, covenant basis (x)5.62x6.18x6.99x8.20x9.77x9.11x8.52x8.00x
60Downside: headroom (EBITDA cushion)19.8%1.1%(11.9%)(31.2%)(56.2%)(82.2%)(70.5%)(59.9%)
61Downside: fixed charge coverage (x)1.20x1.06x0.90x0.72x0.55x0.58x0.61x0.64x
62Downside: liquidity ($000)33,67220,7647,121(6,880)(20,793)(31,774)(42,509)(53,128)
SummaryAssumptionsHistoricalsMgmt CaseLender CaseDownside CaseLoan PricingSources
Covenant headroom, fixed charge coverage and liquidity by quarter for the first two projection years from the covenant headroom block of Compound's Summary tab, unedited. Headroom is the EBITDA cushion, one minus actual over maximum leverage. Liquidity in US$ thousands.

The step-down is 1.25 turns in one quarter, and the cases get there in different shape. The management case holds 16% to 18% of headroom through 2027 and misses the March 2028 test by 1.2% of EBITDA. About 1.2% more last-twelve-month EBITDA at that date would clear it (our arithmetic), and the case passes again in June 2028 at 4.92x. That miss rests on Compound’s assumed 2% revenue growth and 36.5% margin for 2027; company guidance stops at 2026.

The lender case misses by 22.0%. Its covenant test runs on company Adjusted EBITDA, so the miss comes from the operating case. Revenue falling 3% in 2027 and the margin settling near 35% take LTM Adjusted EBITDA down to $83.7 million by FY2028, and once cash runs out there is nothing left to net against debt. The downside’s headroom is 1.1% in March 2027, negative from June 2027, and reaches negative 82.2% in March 2028. For the quarterly test itself, the covenant compliance calculation page works through a certificate clause by clause.

Coverage, free cash flow and liquidity

Scheduled amortization rises from $5.3 million in 2026 to $26.3 million a year from 2028, and fixed charge coverage falls with it: to 1.14x in the management case and below 1.0x from December 2027 in the lender case. The lender case draws the revolver in full and has a funding gap from the third quarter of 2028.

XPOF_Direct_Lending_Underwriting_Model.xlsx
AF101fx=S101
BADAEAFAGAH
5Period end12/31/202612/31/202712/31/202812/31/202912/31/2030
32Adjusted EBITDA, company definition ($000)91,00084,87583,66385,33687,042
34(-) Haircut to addbacks not credited in this case(12,900)(8,025)(5,400)(5,400)(5,400)
35Credited EBITDA, case basis ($000)78,10076,85078,26379,93681,642
44Cash EBITDA ($000)67,80070,72574,51376,18677,892
45(-) Change in working capital incl. deferred revenue(29,065)(9,000)(8,000)(7,000)(7,000)
48Operating cash flow before interest ($000)34,79860,22564,95667,25968,626
50CFADS: cash flow available for debt service ($000)31,35055,98160,71262,93064,210
51(-) Cash interest and fees(56,619)(60,570)(59,839)(56,085)(52,937)
52(-) Scheduled amortization(5,250)(15,750)(26,250)(26,250)(26,250)
53FCF after debt service ($000)(30,519)(20,338)(25,377)(19,405)(14,976)
68Revolver drawn, closing ($000)6,48125,00025,00025,00025,000
75Unrestricted cash ($000)15,00013,181(12,196)(31,600)(46,577)
97Total leverage, credited EBITDA (x)6.74x6.88x6.42x5.96x5.51x
99Total net leverage, covenant basis (x)5.62x6.08x6.01x5.58x5.17x
101Covenant headroom (EBITDA cushion)19.7%2.8%(20.2%)(11.7%)(3.5%)
108Fixed charge coverage (x)1.20x0.95x0.86x0.91x0.97x
110Liquidity: unrestricted cash + undrawn revolver ($000)33,51913,181(12,196)(31,600)(46,577)
112Liquidity in months of fixed charges6.52.1(1.7)(4.6)(7.1)
SummaryAssumptionsHistoricalsMgmt CaseLender CaseDownside CaseLoan PricingSources
Annual columns of Compound's Lender Case tab, FY2026E to FY2030E, a selection of rows from the operating, cash flow, debt and credit statistics blocks. US$ thousands. FY2026E includes the three reported quarters. Negative cash is a funding shortfall the model does not fill with new money.

Three cash drains sit between Adjusted EBITDA and debt service. Cash costs inside the addbacks are still cash out: $14.2 million in the lender case in FY2027. Deferred revenue unwinds as upfront franchise fees are recognized without new cash, after falling $31.7 million in FY2025 and $7.5 million in the nine months of 2026, and the lender case assumes $9.0 million of working capital outflow in 2027. And interest on the floored SOFR plus 6.75% runs at about $60 million a year.

The result is negative free cash flow after debt service in every year of the lender case, $80.1 million in total from FY2027 to FY2030. The management case is positive by $40.4 million over the same years and the downside negative by $150.3 million. In the management case fixed charge coverage falls from 1.43x in December 2026 to 1.14x by September 2028, as the amortization step lands on interest that has not fallen.

XPOF_Direct_Lending_Underwriting_Model.xlsx
E66fx=COUNTIF('Lender Case'!K115:AA115,"FLAG")
BDEFGHI
65TestManagementLenderDownsideThresholdFirst flaggedStatus
66Lender-case total leverage on credited EBITDA above threshold (x)012176.00x12/31/2026FLAG
67Fixed charge coverage below threshold (x)716161.20x12/31/2027FLAG
68Covenant headroom below threshold, any quarter11171720%3/31/2027FLAG
69Downside liquidity below months of fixed charges716166.03/31/2027FLAG
SummaryAssumptionsHistoricalsMgmt CaseLender CaseDownside CaseLoan PricingSources
The four flags from Compound's Summary tab, rows 65 to 69, without the notes column. Counts are flagged quarters from Q4 2026 to Q4 2030; first flagged is the lender case for leverage, the management case for coverage and headroom, and the downside for liquidity.

All four of the request’s flags trip. Lender-case leverage on credited EBITDA is above 6.0x in 12 quarters from December 2026. Fixed charge coverage is below 1.2x in 7, 16 and 16 quarters across the three cases. Headroom is below 20% in 11, 17 and 17 quarters, from March 2027 in the management case. Downside liquidity falls below six months of fixed charges from March 2027 and is negative from September 2027. The management case sits below six months too, at a minimum of 5.3 months, because the model holds $15 million of unrestricted cash and the undrawn revolver is the only other source.

Pricing: all-in yield to take-out and maturity, and the BDC marks

Funded at 96.41% of par and priced off the November 19, 2026 SOFR forward curve, the loan yields 13.28% to a three-year take-out and 12.84% to maturity, about 836 and 790 basis points over average SOFR. Two BDCs carry it at fair values of 97.1% and 96.7% of par.

XPOF_Direct_Lending_Underwriting_Model.xlsx
D19fx=XIRR(N31:N53,D31:D53)
BD
5LOAN TERMS
6Face amount ($000)525,000
7Closing date12/8/2025
8Maturity date12/8/2030
9Take-out date (three-year take-out)12/8/2028
10Original issue discount3.40%
11Other upfront fees0.19%
12Issue price (net funded)96.41%
13Margin over Term SOFR6.75%
14Term SOFR floor1.00%
15Prepayment premium at take-out date0.00%
16Day count basis (days)360
18ALL-IN YIELD
19All-in yield to three-year take-out (annual effective, XIRR)13.28%
20All-in yield to maturity (annual effective, XIRR)12.84%
21Yield to take-out, quarterly-compounded equivalent12.67%
22Yield to maturity, quarterly-compounded equivalent12.27%
23Average floored Term SOFR to take-out (day-weighted)4.31%
24Implied all-in spread to take-out (quarterly-compounded yield less average SOFR)8.36%
25Average floored Term SOFR to maturity (day-weighted)4.37%
26Implied all-in spread to maturity7.90%
27Memo: OID and fees spread evenly over the take-out horizon (per year)1.20%
SummaryAssumptionsHistoricalsMgmt CaseLender CaseDownside CaseLoan PricingSources
Loan terms and yields from Compound's Loan Pricing tab, rows 5 to 27 without the blank row 17. The yields are XIRRs on the lender cash flows of the full $525 million term loan with contractual amortization and no excess cash flow sweep.

The cash flow schedule runs quarterly on ACT/360. Past resets use the rates the filings disclose: 10.92% for the December 2025 stub, then 10.5%, 10.4% and 10.5% through September 2026. For the fourth quarter of 2026 the model uses the 10.82% that HPS Corporate Capital Solutions Fund reports for the loan, where the company disclosed 10.5% at September 30. From January 2027 the base rate is the three-month SOFR forward, 4.32% for the first quarter of 2027, peaking at 4.69% late in 2027 and easing to 4.45% by the end of 2030. The floor never binds. The answer notes that the curve “is not CME Term SOFR”.

The take-out is set on December 8, 2028, the third anniversary, when the prepayment premium has fallen to zero. The yield to take-out is higher than the yield to maturity because the OID and fees, 1.20% a year spread over three years, are earned faster. The SOFR forward curve page covers the curve behind these resets.

XPOF_Direct_Lending_Underwriting_Model.xlsx
L57fx=XIRR(P35:P53,D35:D53)
BCDEFGHIJL
56HolderAs ofSpreadRatePar ($000)Cost ($000)Fair value ($000)Cost % parFV % parYield at mark
57Fortress Private Lending Fund (first lien term loan)9/30/20266.75%10.80%43,10442,55041,84598.7%97.1%12.95%
58HPS Corporate Capital Solutions Fund (first lien term loan)9/30/20266.75%10.82%11,84211,69411,44698.8%96.7%13.11%
SummaryAssumptionsHistoricalsMgmt CaseLender CaseDownside CaseLoan PricingSources
The two public BDC holdings from Compound's Loan Pricing tab, rows 56 to 58, without the mark-versus-cost and model comparison columns. Par, cost and fair value in US$ thousands, from each fund's schedule of investments at September 30, 2026. Yield at mark is to maturity, bought at fair value on September 30, 2026.

Both funds list the loan at SOFR + 6.75%, the model’s margin. Fortress Private Lending Fund holds $43.1 million of par at a cost of 98.7% and a fair value of 97.1%, and HPS Corporate Capital Solutions Fund holds $11.8 million at 98.8% and 96.7%. Both fair values sit below cost, by 1.66% and 2.12% of cost. At those marks, the cash flows to maturity yield 12.95% and 13.11%. The BDC portfolio analysis page reads schedules like these across a portfolio.

What the public filings cannot tell you

The filings give the terms, the reported numbers and the guidance. The inputs that decide this underwriting, covenant EBITDA as the borrower calculates it, the litigation still to come and the 2027 plan, come only from management. Compound’s answer ends with the list, addressed to the sponsor and management.

  • Compliance certificates for Q1 to Q3 2026 with the covenant EBITDA bridge. Run-rate addbacks of up to 25% are allowed, so in the answer’s words “their figure may be higher than the 5.69x I calculate.”
  • A schedule of each litigation matter: amounts paid and accrued, insurance and remaining exposure. About $3.4 million of settlement payments are expected in the fourth quarter of 2026. This replaces the 50% credit.
  • The 2027 budget and projections by brand: openings, closures, same store sales and how much deferred franchise revenue is left to recognize. These replace Compound’s growth and margin assumptions after 2026.
  • A dated plan for the cost review, a 13-week cash flow forecast, and how restricted cash is used.
  • A plan for the March 2028 step-down: an equity cure commitment, an amendment or a refinancing, and how the current strategic review could affect a take-out.

Our view

The model does the work a credit committee needs: it finds the binding constraint, and the constraint is the March 2028 step-down to 5.00x. Whether the loan clears it depends far more on 2027 and 2028 EBITDA growth than on the haircuts, which the covenant test does not use.

The litigation haircut is the right place to start an argument with management. It moves lender EBITDA by $13.6 million, and the company has added litigation back in every year on the sheet. Half credit is a defensible placeholder until a matter-by-matter schedule shows which settlements are finished. On the haircut basis, leverage of 7.9x is the figure to compare against the lender’s own sizing, and it is the reason the 6.0x flag trips from the first projected quarter.

The other side is that the management case misses the step-down by 1.2% of EBITDA on growth and margin that Compound set itself, and covenant EBITDA under the agreement can carry run-rate addbacks the model leaves out. A borrower with a cost review under way and 25% of run-rate capacity has room to report a covenant figure above the model’s. The two BDC marks, about two points below cost at September 30, 2026, are one date’s reading of the loan and sit beside the model, outside its cases.

Three things would change our view: compliance certificates that show the covenant EBITDA the borrower reports, a 2027 budget that sets growth and margins in place of the model’s, and a litigation schedule that shows how much of the $27.1 million recurs. From here the work moves to a credit memo on the loan and, in the downside, a recovery analysis of the first lien.

Xponential direct lending underwriting model (Excel)Compound’s workbook from this run: a Summary with the case results, covenant headroom and flags, an Assumptions sheet with a source or reason beside every input, Historicals with the lender view of each addback, quarterly Management, Lender and Downside cases, Loan Pricing with the BDC marks, and Sources.Download · Free

FAQ

How much addback credit should a direct lender give?

Full credit for non-cash items such as equity compensation and impairment, and partial or no credit for cash costs that recur, such as litigation, restructuring and executive turnover. In this model the haircuts take 24.8% off Xponential’s last-twelve-month Adjusted EBITDA, with a written reason beside each credit percentage.

What is the difference between a lender case and a management case?

The management case follows the company’s guidance and its own Adjusted EBITDA. The lender case lowers growth and margins and haircuts the addbacks the lender does not accept, and it is the case the loan is sized and flagged on. Here the two differ by $18.1 million of FY2027 EBITDA, $10.1 million from the operating assumptions and $8.0 million from the haircuts.

How do you calculate the all-in yield on a term loan with OID?

Take the lender’s cash flows: the funded amount net of OID and fees at close, quarterly interest at the floored base rate plus the margin, amortization, and repayment at par plus any premium at take-out or maturity, then solve for the internal rate of return. Funded at 96.41% of par, this loan yields 13.28% to a three-year take-out and 12.84% to maturity.

Should covenant headroom be measured on leverage or on EBITDA?

Measuring it as an EBITDA cushion, one minus actual leverage over the maximum, says how far EBITDA can fall before a breach, which is the question a lender is asking. On that basis Xponential’s headroom at September 30, 2026 is 18.7%, below the 20% the request set as a flag.

Does covenant EBITDA equal the company's Adjusted EBITDA?

Not necessarily. The credit agreement defines Consolidated EBITDA, and it can permit run-rate cost savings and other addbacks the public figure leaves out, here up to 25% of Consolidated EBITDA. This model uses the company’s Adjusted EBITDA as a proxy and asks for the compliance certificates to confirm it.

CoatueCentri ConsultingAvra783 Capital PartnersOctahedron CapitalArix ResearchCoatueCentri ConsultingAvra783 Capital PartnersOctahedron CapitalArix ResearchCoatueCentri ConsultingAvra783 Capital PartnersOctahedron CapitalArix Research

See this workflow on your own deal

Try it now